Pfizer Strikes $70 Billion Deal with U.S. to Cut Drug Prices and Expand mRNA Research
Washington, D.C., 1 October 2025 — Pharmaceutical giant Pfizer has reached a sweeping $70 billion agreement with the Trump Administration, pledging to lower prescription drug prices for Medicaid patients while investing heavily in U.S. research, development, and manufacturing. The deal, described by both sides as a “landmark agreement,” ties Pfizer’s pricing to a “most-favored-nation” benchmark, […]
Continue Reading